Answers are grounded in this paper and cite their sources.
Inherited cancer susceptibility and tumor microevolution concern different levels of cancer biology. This critical narrative review examines their connections in gastric, colorectal, hepatocellular, biliary tract and pancreatic cancers. We organize the evidence around four processes: mutation acquisition, early clonal establishment, microenvironmental selection and the expansion of resistant clones during treatment. For each process, we distinguish population associations from functional experiments and measurements of somatic lineages within patients. The clearest mechanistic evidence concerns mismatch repair loss in hereditary predisposition, microbial mutagenesis, mutation-specific expansion in normal tissue and repair-associated resistance in pancreatic cancer. Broad ancestry differences and blood methylation associations usually leave the intervening clonal process unresolved. A revised evidence matrix identifies what each study directly measures and what remains to be tested. We describe the assumptions needed to estimate clone abundance and interpret serial ctDNA, then consider applications in surveillance, pretreatment profiling, monitoring and resistance investigation. Methylation and fragmentation measurements may provide complementary information, but their value for guiding treatment requires validation. Connecting susceptibility to tumor evolution will require paired host and tumor measurements that test a specific somatic transition.
No takes yet. Share an insight, caveat, or question.
Potievskiy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: